Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Complaint Against Roche Accepted By ITC

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.S. International Trade Commission has agreed to review Amgen's complaint against Roche regarding Roche's importation of pegylated recombinant human erythropoietin, Amgen announced May 9

You may also be interested in...



Amgen’s ITC Complaint Against Roche’s Peg-EPO Dismissed

U.S. International Trade Commission ruling finds that Roche’s CERA is subject to a clinical trial exemption from patent infringement.

Amgen’s ITC Complaint Against Roche’s Peg-EPO Dismissed

U.S. International Trade Commission ruling finds that Roche’s CERA is subject to a clinical trial exemption from patent infringement.

Roche Continuous Epoetin CERA BLA Submitted For Dosing Every Four Weeks

CERA will have an estimated user fee date of mid February under standard review for treatment of renal anemia.

Related Content

Topics

UsernamePublicRestriction

Register

PS064284

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel